{"nctId":"NCT05248997","briefTitle":"Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis","startDateStruct":{"date":"2022-02-17","type":"ACTUAL"},"conditions":["Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps"],"count":261,"armGroups":[{"label":"rimegepant 75 mg ODT","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: rimegepant 75 mg ODT"]},{"label":"Matching Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Matching placebo"]}],"interventions":[{"name":"rimegepant 75 mg ODT","otherNames":[]},{"name":"Matching placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least two episodes of facial pain/pressure/fullness of moderate or severe intensity on a 4-point rating scale (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) in the past 30 days prior to the Screening Visit.\n* Subject agrees to study-required medication restrictions and the restriction of not starting new medication to treat CRS symptoms during the course of the study.\n* Subject agrees to study-required birth control methods during the course of the study, and female subjects must not be breastfeeding.\n* No clinically significant abnormality identified on the medical or laboratory evaluation.\n\nExclusion Criteria:\n\n* Subject has primary headache disorder.\n* Subject has history of nasal or facial surgery within the 6 months prior to screening.\n* Subject has ongoing rhinitis medicamentosa.\n* Subject has diagnosed or suspected invasive fungal rhinosinusitis.\n* Subject is currently receiving aspirin desensitization or maintenance therapy for Samter's Triad.\n* Subject has a history of recurrent acute sinusitis (four or more episodes per year of acute bacterial rhinosinusitis (ABRS) without signs or symptoms of rhinosinusitis between episodes).\n* Body Mass Index \\> 35.0kg/m2\n* Subject history of exclusionary medical conditions such as HIV disease, cardiovascular conditions, uncontrolled hypertension or diabetes, psychiatric conditions, drug or alcohol abuse, malignancies, drug allergies, or any significant and/or unstable medical conditions.\n* Subjects taking/using excluded therapies.\n* Participation in clinical trial with non-biological investigational agents or investigational interventional treatments.\n* Subjects who have previously participated in any BHV-3000/ BMS-927711/ rimegepant study.\n* Planned participation in any other investigational clinical trial while participating in this clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Facial Pain/Pressure/Fullness on NRS at 2 Hours Post-Dose","description":"Facial pain/pressure/fullness was assessed using an NRS score ranging in integers from 0 to 10, with 0 being \"no facial pain/pressure/fullness\" and 10 being \"worst imaginable facial pain/pressure/fullness.\" Higher scores signified worse condition.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.70","spread":null},{"groupId":"OG001","value":"-2.61","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Nasal Symptom Score (TNSS) at 2 Hours Post-Dose","description":"TNSS was calculated as the sum of 3 symptom scores: facial pain/pressure/fullness, score ranged from 0 (no facial pain/pressure/fullness) to 10 (worst imaginable facial pain/pressure/fullness); nasal obstruction (congestion), score ranged from 0 (no nasal obstruction (congestion) to 10 (worst imaginable nasal obstruction (congestion); and nasal discharge, score ranged from 0 (no nasal discharge) to 10 (worst nasal discharge). TNSS overall score ranged from 0 (no nasal symptom) to 30 (worst nasal symptom); higher scores signified worse condition.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.04","spread":null},{"groupId":"OG001","value":"-6.74","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Nasal Obstruction (Congestion) at 2 Hours Post-Dose","description":"Nasal obstruction (congestion) severity was assessed using a NRS ranging in integers from 0 (no nasal obstruction \\[congestion\\]) to 10 (worst imaginable nasal obstruction \\[congestion\\]). Higher scores signified worse condition.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.48","spread":null},{"groupId":"OG001","value":"-2.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Nasal Discharge at 2 Hours Post-Dose","description":"Nasal discharge severity was assessed using a NRS ranging in integers from 0 (no nasal discharge) to 10 (worst imaginable nasal discharge). Higher scores signified worse condition.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.81","spread":null},{"groupId":"OG001","value":"-1.85","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Headache Pain Relief at 2 Hours Post-Dose","description":"Headache pain relief was defined as a headache pain level of none or mild at 2 hours post-dose on a 4-point Likert scale (0 = None; 1 = Mild; 2 = Moderate; 3 = Severe).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","spread":null},{"groupId":"OG001","value":"55.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Used Rescue Medication Within 24 Hours Post-dose","description":"Post 2 hours after dosing with study medication and after the 2-hour assessments were completed on the e-diary, participants were permitted to use the following rescue medications (non-study medications) such as: acetaminophen or aspirin, ibuprofen, naproxen (or any other type of nonsteroidal anti-inflammatory drug \\[NSAID\\]), oral antihistamines (non- sedating), oral decongestants, topical nasal decongestants, topical nasal anticholinergics.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":99},"commonTop":["Diarrhoea","Nausea","Aspartate aminotransferase increased","Blood creatine phosphokinase increased","Electrocardiogram PR shortened"]}}}